Key clinical point: Sequential chemoradiotherapy and immunotherapy appears safe and efficacious for treating node-positive cervical cancer.
Major finding: The rate of grade 3 toxicity was 9.5%; the 12-month overall survival and progression-free survival rates were 90% and 81%, respectively.
Study details: A multicenter phase 1 trial among 32 women having stage IB2 to IVA cervical cancer with positive pelvic and/or para-aortic lymph nodes.
Disclosures: Dr. Mayadev disclosed receiving a grant from the National Cancer Institute during the conduct of the study, personal fees from AstraZeneca, grants from NRG Oncology, and personal fees and nonfinancial support from the Gynecology Oncology Group Foundation outside the submitted work; receiving compensation for serving on the advisory board of Varian Medical Systems in 2018; and being a speaker for Samsung Medical Systems in 2017. The study was supported by the National Cancer Institute and by institutional funds.
Mayadev JS et al. JAMA Oncol. 2019 Nov 27. doi: 10.1001/jamaoncol.2019.3857.